HK Stock Market Move | HANXBIO-B(03378) rose nearly 7% in the afternoon and was included in the FTSE Global Equity Microcap Index. The company's heavyweight products made their debut at the AACR annual meeting.

HANXBIO-B (03378) rose nearly 7% in the afternoon, up 6.99% at the time of the report, to 28.48 Hong Kong dollars with a turnover of 9.5572 million Hong Kong dollars. On the news front, recently, HANXBIO-B announced that according to FTSE Russell's quarterly review of the FTSE Global Equity Index Series, HANSIATECH has been included in the FTSE Global Micro Cap Index. The inclusion took effect after the close of trading on June 19, 2026 (Friday). Previously, at the 2026 American Association for Cancer Research (AACR) annual meeting, HANXBIO-B unveiled four core preclinical research achievements, including the CTLA-4/SIRP dual-function fusion protein HX044, the bispecific antibody-drug conjugate HX116, the PD-L1-targeted ADC HX112, and the 3D tumor organ ADC evaluation system, further confirming the company's research and development strength and innovation capabilities.